Intel Sells Altera Stake, Goldman Sachs Earnings, and Pfizer's Obesity Drug Setback

Intel's Strategic Divestment of Altera

• 🎯 Intel is selling a 51% stake in its programmable chips unit, Altera, to Silver Lake Management for an undisclosed sum, aiming to raise cash and divest non-core assets.
• 💡 The new CEO is focusing on turning around Intel's foundry business, with Altera and Mobileye identified as potential assets to sell.
• 📉 Intel originally paid over $16 billion for Altera a decade ago, indicating a significant valuation discount in the current sale.
• 🤝 Silver Lake's involvement suggests a belief in leveraging Altera within the booming semiconductor space, particularly in AI.

Goldman Sachs Earnings and Financial Sector Trends

• 📊 Goldman Sachs reported better-than-expected earnings, primarily driven by strong performance in its equity trading desk.
• ⚠️ Despite strong trading revenue, investment banking revenue was down 8% year-over-year due to macro uncertainty impacting M&A and equity deals.
• 📈 The bank is focusing on client relationships and financing revenue, with a growing backlog of deals, though execution remains key.
• 🏦 Overall bank earnings indicate strong trading fees but weaker overall fees, with a focus on buybacks and conservative credit provisions amidst uncertainty.
• ✂️ Headcount reductions are being signaled at firms like Goldman Sachs and Morgan Stanley, reflecting cautious revenue outlooks.

Pfizer's Obesity Drug Development Setback

• 🚫 Pfizer has halted development of its experimental obesity pill, danuglipron, citing concerns linked to liver damage.
• 💰 This setback is a significant sentiment issue for Pfizer in the highly competitive and potentially hundred-billion-dollar obesity market.
• 📉 Pfizer is already trailing competitors like Eli Lilly and Novo Nordisk in this space, and this failure adds to mid-to-long-term growth concerns.
• 🚀 The company will likely need to pursue external assets or M&A to remain competitive in the obesity market, possessing significant M&A firepower.
• 💡 Other players like Viking Therapeutics and smaller biotechs are advancing oral GLP-1 drugs for obesity, with major pharmaceutical companies also investing in this area.